Anaplastic Astrocytoma: Pipeline Review H1 2018 - Covering Therapeutics Under Development by Companies/Universities/Institutes - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Anaplastic Astrocytoma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Anaplastic Astrocytoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Astrocytoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 9, 10 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 2 molecules, respectively.

Key Topics Covered

Introduction Anaplastic Astrocytoma - Overview Anaplastic Astrocytoma - Therapeutics Development Anaplastic Astrocytoma - Therapeutics Assessment Anaplastic Astrocytoma - Companies Involved in Therapeutics Development Anaplastic Astrocytoma - Drug Profiles Anaplastic Astrocytoma - Dormant Projects Anaplastic Astrocytoma - Discontinued Products Anaplastic Astrocytoma - Product Development Milestones Appendix

Companies Mentioned

AbbVie Inc Aduro BioTech Inc Advantagene Inc AngioChem Inc Astellas Pharma Inc Bayer AG Boehringer Ingelheim GmbH Burzynski Research Institute Inc Deciphera Pharmaceuticals LLC Ipsen SA Millennium Pharmaceuticals Inc Novartis AG Orbus Therapeutics Inc Pfizer Inc Tocagen Inc TVAX Biomedical Inc Ziopharm Oncology Inc

For more information about this report visit https://www.researchandmarkets.com/research/mq3gtv/anaplastic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005505/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Brain Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 04:49 AM/DISC: 06/06/2018 04:49 AM


Update hourly